Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Cisplatin in cancer treatment
AMP Romani - Biochemical pharmacology, 2022 - Elsevier
Cisplatin is a widely used chemotherapy agent in the treatment of various forms of
carcinomas and sarcomas. Its effectiveness in delaying negative outcome in cancer patients …
carcinomas and sarcomas. Its effectiveness in delaying negative outcome in cancer patients …
The rediscovery of platinum-based cancer therapy
S Rottenberg, C Disler, P Perego - Nature Reviews Cancer, 2021 - nature.com
Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …
approved in 1978. More than 40 years later, even in the era of precision medicine and …
[HTML][HTML] Introduction to traditional medicine and their role in prevention and treatment of emerging and re-emerging diseases
SAA Rizvi, GP Einstein, OL Tulp, F Sainvil, R Branly - Biomolecules, 2022 - mdpi.com
Infectious diseases have been a threat to human health globally. The relentless efforts and
research have enabled us to overcome most of the diseases through the use of antiviral and …
research have enabled us to overcome most of the diseases through the use of antiviral and …
The DNA damage response to transcription stress
The spatiotemporal control of RNA polymerase II (Pol II)-mediated gene transcription is
tightly and intricately regulated. In addition, preservation of the integrity of the DNA template …
tightly and intricately regulated. In addition, preservation of the integrity of the DNA template …
Metal drugs and the anticancer immune response
B Englinger, C Pirker, P Heffeter, A Terenzi… - Chemical …, 2018 - ACS Publications
The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …
Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment
L Kang, Y Tian, S Xu, H Chen - Journal of Neurology, 2021 - Springer
Oxaliplatin (OXA) is a commonly used platinum-based chemotherapy drug for colorectal
cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of …
cancer. OXA-induced peripheral neurotoxcity (OIPN) is a comprehensive adverse reaction of …
Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors
J García-Foncillas, Y Sunakawa, D Aderka… - Frontiers in …, 2019 - frontiersin.org
Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the
epidermal growth factor receptor (EGFR), and both are widely used in combination with …
epidermal growth factor receptor (EGFR), and both are widely used in combination with …
[HTML][HTML] Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents
Cisplatin has dramatically improved the survival rate of cancer patients, but it has also
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …
Chemotherapy-induced peripheral neuropathy: Current status and progress
JR Brewer, G Morrison, ME Dolan, GF Fleming - Gynecologic oncology, 2016 - Elsevier
As there are increasing numbers of cancer survivors, more attention is being paid to the long
term unwanted effects patients may experience as a result of their treatment and the impact …
term unwanted effects patients may experience as a result of their treatment and the impact …
[HTML][HTML] Long-term toxicity of cisplatin in germ-cell tumor survivors
Context Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach,
including cisplatin-based chemotherapy has resulted in cure in the majority of patients with …
including cisplatin-based chemotherapy has resulted in cure in the majority of patients with …